Unveiling a pH-Responsive Dual-Androgen-Blocking Magnetic Molecularly Imprinted Polymer for Enhanced Synergistic...

Area of Science:

• Oncology
• Materials Science
• Nanotechnology

Background:

• Prostate cancer is a leading malignancy in men, with androgens playing a key role in its development.
• Androgen receptor (AR) inhibition is a primary therapeutic strategy for prostate cancer.
• Existing therapies face challenges in targeted delivery and synergistic effects.

Purpose of the Study:

• To design and synthesize a novel pH-responsive dual androgen-blocking nanodrug (FASC MIPs) for enhanced prostate cancer therapy.
• To evaluate the selective testosterone sequestration and targeted delivery of bicalutamide by FASC MIPs.
• To assess the in vitro and in vivo efficacy and safety of FASC MIPs in prostate cancer models.

Main Methods:

• Synthesis of a molecularly imprinted polymer-based nanodrug (FASC MIPs) incorporating chitosan for pH responsiveness.
• In vitro studies using LNCaP prostate cancer cells to assess cell growth inhibition and cell cycle effects.
• In vivo studies using a prostate cancer xenograft mouse model to evaluate antitumor properties and safety.

Main Results:

• FASC MIPs demonstrated selective testosterone sequestration and targeted delivery of bicalutamide in a simulated tumor microenvironment.
• The nanodrug exhibited significant inhibition of LNCaP cell proliferation by blocking the G1 phase of cytokinesis.
• In vivo studies showed excellent antitumor efficacy in a xenograft mouse model with no observed adverse effects on healthy tissues.

Conclusions:

• The developed FASC MIPs show promising pH-responsive, dual androgen-blocking capabilities for synergistic prostate cancer therapy.
• This nanodrug strategy offers a novel approach to enhance therapeutic outcomes in prostate cancer treatment.
• The findings support the potential of FASC MIPs for future clinical translation in managing prostate cancer.